Suppliers and packagers for LANOXIN PEDIATRIC

LANOXIN PEDIATRIC

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Covis	LANOXIN PEDIATRIC	digoxin	INJECTABLE;INJECTION	009330	NDA	Covis Pharma US, Inc	70515-261-10	10 VIAL in 1 BOX (70515-261-10) / 2 mL in 1 VIAL	2019-10-29
Covis	LANOXIN PEDIATRIC	digoxin	INJECTABLE;INJECTION	009330	NDA	Covis Pharma US, Inc	70515-263-10	10 VIAL in 1 BOX (70515-263-10) / 1 mL in 1 VIAL	2019-10-29

Suppliers for the Pharmaceutical Drug: LANOXIN PEDIATRIC

Last updated: August 8, 2025

Introduction

Lanoxin Pediatric, the pediatric formulation of digoxin, remains a critical medication in managing heart failure and arrhythmias in children. As a narrow therapeutic index drug, the supply chain for Lanoxin Pediatric involves stringent quality controls, regulatory oversight, and a network of manufacturers capable of producing pediatric-specific formulations. This article provides a comprehensive overview of current key suppliers, manufacturing landscape, regulatory considerations, and market dynamics surrounding Lanoxin Pediatric.

---

Manufacturers of Lanoxin Pediatric: An Overview

Historically, AbbVie (formerly part of GlaxoSmithKline) has been the primary supplier of Lanoxin (digoxin), including its pediatric formulations. The original production of digoxin and its pediatric variant has been aligned with the brand’s patent and manufacturing rights.

Key Suppliers and Manufacturing Entities

1. AbbVie (AbbVie Inc.)

• Market Role: As the incumbent and most prominent provider, AbbVie supplies Lanoxin Pediatric across multiple markets, leveraging its established manufacturing facilities.
• Product Portfolio: Their portfolio includes both adult and pediatric formulations, with a focus on maintaining supply stability and dosage precision for pediatric applications.
• Regulatory Status: Their manufacturing complies with the U.S. FDA regulations, EMA standards, and other regional authorities, ensuring high-quality standards.

2. Mylan (Now part of Viatris)

• Generic Availability: Mylan, acquired by Viatris, has historically produced generic digoxin, including pediatric formulations. They serve as a significant alternative supplier, especially in markets where brand-name drugs are less accessible.
• Manufacturing Capabilities: Mylan’s extensive global facilities enable broad distribution and competitive pricing.

3. Teva Pharmaceutical Industries

• Generic Digoxin: Teva offers generic digoxin products, including pediatric formulations, through its global manufacturing network.
• Regulatory Approvals: Their manufacturing processes adhere to rigorous quality standards, with multiple formulations approved in various jurisdictions.

4. Other Generic Manufacturers

Several regional generic manufacturers supply digoxin pediatric formulations, primarily to emerging markets. Examples include Kusum Healthcare, Sandoz (a Novartis division), and Sun Pharmaceutical Industries.

---

Regulatory Landscape and Compliance

Suppliers of Lanoxin Pediatric operate within tightly regulated frameworks owing to the drug’s narrow therapeutic window. Key regulatory requirements include:

• FDA Approval: Manufacturers must submit New Drug Applications (NDAs) or Abbreviated New Drug Applications (ANDAs) to the FDA, demonstrating bioequivalence, safety, and manufacturing quality.
• EMA Compliance: European manufacturers must meet EMA standards, with marketing authorization via the centralized or decentralized procedures.
• Good Manufacturing Practices (GMP): All suppliers must adhere to GMP standards to ensure drug consistency, potency, and safety.

Quality Control Measures

Given the drug’s critical dosing requirements in children, suppliers implement rigorous testing for bioavailability, stability, and potency. Differences often exist in excipients and formulation adjustments tailored for pediatric use, demanding precise quality assurance.

---

Supply Chain Challenges and Market Dynamics

1. Patent and Market Exclusivity

The original patent for digoxin has long expired, leading to a proliferation of generic manufacturing, which in turn stabilizes supply but intensifies competition.

2. Manufacturing Complexities

Developing pediatric formulations is complex due to dosage-specific requirements, taste-masking, and stability issues. Suppliers must invest in specialized formulations, which can impact supply consistency.

3. Global Demand Fluctuations

Demand peaks in pediatric cardiology, especially in countries with aging populations and high congenital heart disease prevalence. Supply chains must adapt to regional needs, leading to sourcing from multiple manufacturers.

4. Regulatory Hurdles

Stringent regulatory approvals and variations across regions influence supplier options, often limiting the number of approved manufacturers within certain markets.

---

Emerging Trends and Future Outlook

• Enhanced Manufacturing Capabilities: Companies are investing in advanced formulation techniques, such as orodispersible tablets or liquid preparations, to improve compliance.
• Regional Manufacturing Growth: Countries like India and China are expanding their production capacities, aiming to serve both domestic and export markets.
• Supply Chain Resilience: The COVID-19 pandemic highlighted vulnerabilities; thus, pharma companies are diversifying supplier bases and establishing strategic stockpiles for critical drugs like Lanoxin Pediatric.

---

Conclusion

The supply of Lanoxin Pediatric primarily hinges on well-established manufacturers like AbbVie, alongside reputable generic producers such as Viatris (formerly Mylan) and Teva. With high regulatory standards, market maturity, and the demand for pediatric formulations, these companies maintain a robust supply chain. However, ongoing challenges include formulation complexities and regional regulatory variances, which influence market dynamics.

---

Key Takeaways

• Leading suppliers of Lanoxin Pediatric include AbbVie, Viatris (Mylan), and Teva, ensuring broad access across regions.
• Regulatory compliance with FDA, EMA, and other authorities remains pivotal in maintaining manufacturing and distribution.
• The landscape is evolving with increased focus on innovative pediatric formulations and regional manufacturing hubs.
• Supply chain resilience depends on diversification, regulatory adherence, and technological advancements.
• Market demand underscores the necessity for continuous quality assurance and capacity expansion to meet pediatric healthcare needs.

---

FAQs

1. Who are the main global suppliers of Lanoxin Pediatric?
Answer: The primary global suppliers include AbbVie, Viatris (formerly Mylan), and Teva Pharmaceutical Industries, offering both brand-name and generic formulations.

2. Are there regional differences in Lanoxin Pediatric availability?
Answer: Yes, supply varies based on regional manufacturing permissions, regulatory approval, and market demand, with some countries relying more heavily on generic manufacturers.

3. What regulatory agencies oversee the quality of Lanoxin Pediatric?
Answer: The FDA (United States), EMA (Europe), and national agencies in other countries enforce manufacturing standards, requiring compliance with GMP protocols.

4. How do formulation challenges impact the supply of Lanoxin Pediatric?
Answer: Pediatric formulations demand specialized excipients, taste-masking, and dosage forms, complicating manufacturing and potentially affecting supply stability.

5. What future trends are shaping the supply chain for Lanoxin Pediatric?
Answer: Trends include innovation in pediatric formulations, regional manufacturing expansion, and increased focus on supply chain resilience to ensure continuous availability.

---

References

1. U.S. Food and Drug Administration (FDA). Drug Approval & Quality.
2. European Medicines Agency (EMA). Marketing Authorization.
3. Viatris Inc. Company Reports, 2022.
4. Teva Pharmaceutical Industries Ltd. Product Portfolio and Regulatory Filings, 2022.
5. Market Research Reports on Digoxin and Pediatric Cardiology Drugs, 2022.